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Background. The etiologic inference of identifying a pathogen in the upper respiratory tract (URT) of children with pneumonia 
is unclear. To determine if viral load could provide evidence of causality of pneumonia, we compared viral load in the URT of chil-
dren with World Health Organization–defined severe and very severe pneumonia and age-matched community controls.
Methods. In the 9 developing country sites, nasopharyngeal/oropharyngeal swabs from children with and without pneumonia 
were tested using quantitative real-time polymerase chain reaction for 17 viruses. The association of viral load with case status was 
evaluated using logistic regression. Receiver operating characteristic (ROC) curves were constructed to determine optimal discrim-
inatory viral load cutoffs. Viral load density distributions were plotted.
Results. The mean viral load was higher in cases than controls for 7 viruses. However, there was substantial overlap in viral load 
distribution of cases and controls for all viruses. ROC curves to determine the optimal viral load cutoff produced an area under the 
curve of <0.80 for all viruses, suggesting poor to fair discrimination between cases and controls. Fatal and very severe pneumonia 
cases did not have higher viral load than less severe cases for most viruses.
Conclusions. Although we found higher viral loads among pneumonia cases than controls for some viruses, the utility in using viral 
load of URT specimens to define viral pneumonia was equivocal. Our analysis was limited by lack of a gold standard for viral pneumonia.
Keywords. pneumonia; viral load; viral density; RSV; PERCH.
 
For diagnosing viral pneumonia, upper respiratory tract (URT) 
specimens have become the most common specimen type due 
to their logistical ease of collection [1, 2]. However, detection 
of viruses in URT specimens has low specificity as this finding 
might simply reflect an URT infection without lower respira-
tory tract involvement or coincidental asymptomatic or past 
infection [2–4].
A possible solution to the lack of specificity of simply detect-
ing the presence or absence of a virus in the URT of pneumo-
nia patients is to determine whether the density of a virus in 
the URT can better distinguish its causative role in pneumo-
nia. There are reports that a higher pathogen load in the URT is 
associated with pneumonia, for both Streptococcus pneumoniae 
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and some respiratory viruses [5–8]. In addition, for some 
viruses, higher viral load in the URT has been associated with 
worse outcomes [7, 9–11].
In this analysis, we describe viral load in nasopharyngeal/
oropharyngeal (NP/OP) specimens from cases and community 
controls from a large multicountry childhood pneumonia study 
(Pneumonia Etiology Research for Child Health [PERCH]), as 
well as demographic and clinical characteristics associated with 
higher viral load and disease severity. An overarching aim was 
to explore whether the incorporation of viral load data into the 
main PERCH etiology analysis might improve the assignment 
of the etiology of pneumonia cases.
METHODS
The PERCH study design and enrollment strategy has been 
previously described [12]. In brief, PERCH is a case-control 
study of the etiology of World Health Organization (WHO)–
defined severe and very severe pneumonia among hospital-
ized children aged 1–59 months and age frequency-matched 
community controls. Enrollment took place during August 
2011–January 2014 for 24  months at each of 9 study sites 
located in 7 countries—Dhaka and Matlab, Bangladesh; 
Basse, The Gambia; Kilifi, Kenya; Bamako, Mali; Soweto, 
South Africa; Nakhon Phanom and Sa Kaeo, Thailand; and 
Lusaka, Zambia [13].
Case and Control Definitions
For this analysis, we included only cases with evidence of 
pneumonia on chest radiograph, defined as consolidation 
and/or any other infiltrate assessed according to the WHO 
radiological pneumonia criteria [14]. A control participant 
was considered to have a respiratory tract illness (RTI) if 
cough or runny nose was reported. RTI was also considered 
present if a child had (1) at least 1 of ear discharge, wheezing, 
or difficulty breathing and (2) either a measured temperature 
of ≥38.0°C within the previous 48 hours or a history of sore 
throat. Controls who did not meet the definition of RTI are 
referred to as non-RTI controls.
Specimen Collection and Laboratory Testing
Nasopharyngeal and oropharyngeal swabs were collected from 
PERCH cases and controls at enrollment. Nasopharyngeal 
specimens were collected by inserting flocked swabs (Copan 
ETC) into the posterior nasopharynx and rotating 180° for 2–3 
seconds. Oropharyngeal specimens were then collected by rub-
bing Rayon swabs (Fisher Scientific) over both tonsillar pillars 
and the posterior oropharynx for several seconds. Following 
collection, swabs were placed together in the same 3-mL vial 
of universal transport media (Copan) and processed within 24 
hours of collection. Specimens were left at room temperature 
for no more than 2 hours or at 4°C for no more than 24 hours, 
before freezing at –70°C.
All specimens were tested in-country using a standard-
ized methodology, and details are described elsewhere [15]. 
Specimens were evaluated using the Fast-track Diagnostics 
Respiratory Pathogens 33 test (FTD Resp 33, Fast-track 
Diagnostics, Sliema, Malta), a 33-target, 8-multiplex real-time 
polymerase chain reaction (PCR) platform for the detection 
of viruses, bacteria, and fungi. The 18 viruses or virus classes 
included influenza A, B, and C viruses; parainfluenza virus 
(PIV) types 1, 2, 3, and 4; coronaviruses NL63, 229E, OC43, 
and HKU1; human metapneumovirus (HMPV) A and B (A 
and B not differentiated); rhinovirus; respiratory syncytial 
virus (RSV) A and B (A and B not differentiated); adenovirus; 
enterovirus and parechovirus (not differentiated); human boca-
virus (HBOV); and cytomegalovirus. Cytomegalovirus is not 
included in this analysis but is discussed in a separate publica-
tion of the pathogen load of pathogens commonly detected in 
both cases and controls [16].
Some sites (Bangladesh, The Gambia, Mali, South Africa) 
collected lung aspirates from children with consolidation on 
chest radiograph who met clinical and radiologic criteria for the 
Table  1. Characteristics of Chest Radiograph–Positive Children With 
Severe and Very Severe Pneumonia and Controls—Pneumonia Etiology 





(n = 4986) χ2 P Valueb
Site
 Kenya 282 (16.3) 855 (17.2) <.001
 The Gambia 273 (15.8) 624 (12.5)
 Mali 239 (13.8) 724 (14.5)
 Zambia 189 (10.9) 535 (10.7)
 South Africa 433 (25.0) 823 (16.5)
 Thailand 98 (5.7) 657 (13.2)
 Bangladesh 219 (12.6) 768 (15.4)
Age
 1–5 mo 680 (39.2) 1555 (31.2) <.001
 6–11 mo 415 (24.0) 1187 (23.8)
 12–23 mo 424 (24.5) 1235 (24.8)
 24–59 mo 214 (12.4) 1009 (20.2)
Female sex 756 (43.6) 2477 (49.7) <.001
Prior antibiotic usec 597 (42.4) 84 (1.7) <.001
Respiratory tract 
illnessd
NA 1185 (23.8) NA
No. of viruses detected
 0 viruses 180 (10.4) 1048 (21.0)
 1 virus 628 (36.2) 1928 (38.7) <.001
 2 viruses 616 (35.6) 1420 (28.5)
 ≥3 viruses 309 (17.8) 590 (11.8)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CXR+, chest radiograph positive; NA, not applicable.
aCXR+ defined as having radiographic evidence of pneumonia.
bComparing distribution of characteristics between CXR+ cases and controls. Bolded val-
ues are significant (P < .05).
cPrior antibiotic use: administered antibiotics at the study facility prior to the collection 
of specimens (cases only), antibiotics at a referral facility (cases only), or positive serum 
bioassay (cases and controls).
dSee Methods for respiratory tract illness definition.
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procedure [17]. Lung aspirate specimens were tested for viral 
targets using the same method described for NP/OP specimens.
Statistical Analysis
Human immunodeficiency virus (HIV)–positive cases were 
excluded from analyses unless stated otherwise. PCR quan-
tification was log10-transformed. Demographic characteris-
tics of cases and controls were compared using the χ2 test. All 
controls, both RTI and non-RTI, were included in the main 
analysis. All analyses of viral load were restricted to children 
positive for each virus. Among children positive for each virus, 
t tests adjusted for site and age were performed to compare 
mean cycle threshold (Ct) values between cases and controls. 
For each virus, a trend analysis, using simple linear regression, 
was performed to test if viral density increased with age for 
cases and for controls. Among cases only, mean Ct values were 
also compared by days since onset, severity, vital status, and 
HIV status. Multivariable logistic regression, adjusting for age 
and site, was performed to compare odds of being a case for 
each 3.4-unit drop in Ct value, which was approximately equiv-
alent to a 1 log10 increase in viral copies/mL; Ct values instead 
of viral density were used for regression because viral density 
was only accurate within the linear range of the assay (104–108 
copies/mL). Kernel density distribution plots were created 
to show distributions of viral density by case/control status. 
Receiver operating characteristic (ROC) curves and the corre-
sponding area under the curve (AUC) were generated to inves-
tigate the performance of viral load in determining case status 
among children positive by NP/OP PCR for each virus, and the 
Youden index was calculated to determine the optimized diag-
nostic cutoffs to differentiate cases and controls [18]. To guard 
against bias in the estimates of sensitivity due to having a small 
number of some viruses detected among cases, the Youden 
index was calculated using leave-one-out cross-validation 
where sample size was sufficient [19]. Redefining positivity 
using the optimal cutpoints, we calculated odds ratios associ-
ated with case status for children above vs below the optimal 
cutpoint including negatives. The proportion of radiograph-
ically confirmed cases attributable to each virus [population 
attributable fraction: population prevalence × (1 – 1 / OR)] was 
calculated using 2 methods: (1) any positive vs negative and 
(2) positive above vs below the optimal cutpoint, the former 
method being optimal for laboratory sensitivity and the latter 
for a balance of epidemiological sensitivity and specificity. All 
analyses were performed using SAS software version 9.4 (SAS 
Institute, Cary North Carolina) and R Statistical Software 3.2.1 
(R Foundation for Statistical Computing, Vienna, Austria). All 
P values are 2 sided.
Table 2. Mean Nasopharyngeal/Oropharyngeal Polymerase Chain Reaction Cycle Threshold Values for Chest Radiograph–Positive Cases and Controls 
and Odds Ratios for Viral Load Being Predictive of Case Status—Pneumonia Etiology Research for Child Health (PERCH) Study, August 2011–January 2014
Virus
CXR+ Casesa (n = 1733) All Controls (n = 4986)
P Valued
OR per 1 Log10 Increase, 
Copies/mL (95% CI)eNo.b (%)b
Ct Value Meanc 
(95% CI) No.b (%)b
Ct Value Meanc 
(95% CI)
Adenovirus 164 (9.5) 27.7 (26.8–28.5) 594 (11.9) 29.5 (29.2–29.8) <.001 1.27 (1.10–1.46)
Coronavirus 229 18 (1.1) 31.1 (28.6–33.5) 54 (1.1) 30.2 (28.3–32.0) .58 0.89 (.62–1.26)
Coronavirus 43 38 (2.2) 26.4 (24.4–28.5) 192 (3.9) 28.0 (27.1–28.8) .30 1.13 (.91–1.39)
Coronavirus 63 36 (2.1) 27.0 (25.3–28.7) 158 (3.2) 28.5 (27.7–29.3) .26 1.18 (.90–1.55)
Coronavirus HKU 37 (2.2) 29.2 (27.0–31.4) 111 (2.2) 27.7 (26.5–28.9) .40 0.91 (.74–1.13)
Influenza A 62 (3.6) 28.5 (27.7–29.4) 57 (1.2) 29.8 (28.4–31.2) .31 1.21 (.85–1.72)
Influenza B 18 (1.1) 27.6 (25.7–29.5) 29 (0.6) 28.5 (26.7–30.3) .82 1.07 (.63–1.83)
Influenza C 10 (0.6) 28.1 (24.8–31.4) 29 (0.6) 27.3 (25.3–29.3) .14 0.44 (.17–1.15)
HBOV 231 (13.4) 30.5 (29.6–31.3) 660 (13.3) 31.7 (31.3–32.1) .007 1.13 (1.03–1.24)
HMPV A/B 185 (10.8) 28.1 (27.6–28.7) 206 (4.1) 28.9 (28.2–29.5) .02 1.23 (1.03–1.46)
Parainfluenza 1 89 (5.2) 26.1 (24.9–27.2) 49 (1.0) 29.4 (27.6–31.2) .008 1.37 (1.08–1.74)
Parainfluenza 2 23 (1.3) 34.0 (31.7–36.3) 53 (1.1) 35.1 (33.9–36.3) .70 1.10 (.71–1.69)
Parainfluenza 3 104 (6.1) 25.0 (24.0–25.9) 142 (2.9) 29.0 (28.0–30.0) <.001 1.47 (1.22–1.77)
Parainfluenza 4 44 (2.6) 31.7 (30.3–33.1) 86 (1.7) 32.2 (31.3–33.1) .88 0.98 (.73–1.31)
PV/EV 131 (7.6) 30.1 (29.5–30.8) 423 (8.5) 30.4 (30.0–30.7) .45 1.08 (.89–1.31)
Rhinovirus 365 (21.2) 31.7 (31.3–32.0) 1056 (21.2) 32.4 (32.3–32.6) .003 1.21 (1.08–1.35)
RSV 461 (26.8) 22.2 (21.8–22.5) 140 (2.8) 27.0 (26.1–28.0) <.001 2.02 (1.71–2.37)
Abbreviations: CI, confidence interval; Ct, cycle threshold; CXR+, chest radiograph positive; HBOV, human bocavirus; HMPV, human metapneumovirus; OR, odds ratio; PV/EV, parechovirus/
enterovirus; RSV, respiratory syncytial virus.
aCXR+ defined as having radiographic evidence of pneumonia.
bNo. (%) positive in the nasopharynx/oropharynx among those with available results for the given virus.
cAmong those with a positive density.
dComparing mean cycle threshold value of CXR+ cases vs all controls using linear regression adjusting for age and site. Bolded values are significant (P < .05).
eOdds ratio is for approximately each 3.4-unit drop in Ct value (equivalent to approximately 1 log10 increase in copies/mL) adjusting for age and site using logistic regression. Bolded values 
are significant (P < .05).
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Ethical Considerations
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at the Johns Hopkins Bloomberg School of 
Public Health. Parents or guardians of all participants provided 
written informed consent.
RESULTS
Of 1935 radiographically confirmed cases and 5325 controls in 
PERCH, 1733 cases (1227 severe, 506 very severe) and 4986 con-
trols (1185 RTI and 3801 non-RTI) were not known to be HIV 
infected and had viral density results available for analysis (Table 1).
Overall, 89.6% of cases and 79.0% of controls had at least 
1 virus detected, and 53.4% and 40.3%, respectively, had ≥2 
viruses detected (Table 1). Among the 17 viruses tested, RSV 
was the most commonly detected among cases (27%) but was 
uncommon among controls (3%) (Table 2). Rhinovirus was the 
next most commonly detected virus in cases but was present at 
a similar frequency among controls (21% for both).
Analysis of Viral Load Among Cases and Controls
RSV had the highest mean viral load among cases (7.3 log cop-
ies/mL; Figure 1); no viruses other than RSV had a mean viral 
load >6 log copies/mL. Among controls, no viruses had a mean 
viral load >6 log copies/mL. Eight viruses among cases (RSV, 
influenza C, PIV1, PIV3, PIV4, coronavirus 43, coronavirus 
63, and HMPV) had mean viral loads >5 log copies/mL vs 5 
viruses among controls (RSV, influenza C, PIV4, coronavirus 
43, and coronavirus 63). There were 7 viruses that had signif-
icantly higher mean viral density among cases after adjusting 
for site and age—adenovirus, HBOV, HMPV, PIV1, PIV3, rhi-
novirus, and RSV. After adjusting for age and site, there was 
a significant increase in the odds of being a case (vs a con-
trol) for each 3.4-unit drop in Ct value (approximately 1 log 
increase in copies/mL) for the same 7 viruses, ranging from a 
13% increased odds for HBOV to a 102% increased odds for 
RSV (Table 2).
Viral load was similar between RTI and non-RTI controls for 
most viruses with the exception of RSV, where the mean viral load 
was significantly higher for RTI controls (Supplementary Figure 1).
Despite the differences in viral load between cases and con-
trols noted above, there was substantial overlap in the viral den-
sity distribution between cases and controls in which virus was 
detected, as shown in the box plots and kernel density distri-
bution plots (Figures 1 and 2). Kernel density distribution plots 
were examined for a bimodal distribution with a smaller subset 
Figure 1. Nasopharyngeal/oropharyngeal viral load (log10 copies/mL) for chest radiograph–positive (CXR+) cases and all controls among those in which the virus was 
detected—Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. CXR+ defined as having radiographic evidence of pneumonia. Box-and-
whiskers plot features include the following: central line in box is median, bottom line of box is first quartile (25%), top line of box is third quartile (75%), diamond is mean, 
and top and bottom of whiskers represent 95% confidence intervals. Area above the upper dotted line and below the lower dotted line indicate areas outside the linear range 
of the assay for calculation of viral load from cycle threshold (Ct) values where there is a greater degree of uncertainty in viral density calculations. Numbers on x-axis indicate 
number of positive results for that virus. *P value comparing mean Ct value between controls and CXR+ cases <.05 after adjusting for age and site. Abbreviations: Adeno, 
adenovirus; Boca, human bocavirus; CXR, chest radiograph; Flu, influenza virus; HCoV, human coronavirus; HMPV, human metapneumovirus; Para, parainfluenza virus; PV/EV, 
parechovirus/enterovirus; Rhino, rhinovirus; RSV, respiratory syncytial virus. 
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Figure 2. Kernel density distribution plots comparing nasopharyngeal/oropharyngeal (NP/OP) viral load among chest radiograph–positive (CXR+) cases and all controls for 
each viral polymerase chain reaction (PCR) target—Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. Tick marks across the top of 
each plot indicate viral load of each individual (first row of black ticks for cases and second row of gray ticks for controls). Dashed curves indicate areas outside the linear 
range of the assay for calculation of viral load from cycle threshold values. Dotted dashed vertical lines indicate optimal cutpoint distinguishing cases and controls calculated 
using Youden index. Black arrows in adenovirus and human metapneumovirus plots indicate NP/OP viral load of cases whose lung aspirate specimen was available and 
PCR positive for that virus. Abbreviations: Adeno, adenovirus; Boca, human bocavirus; CXR, chest radiograph; Flu, influenza virus; HCoV, human coronavirus; HMPV, human 
metapneumovirus; Para, parainfluenza virus; PV/EV, parechovirus/enterovirus; Rhino, rhinovirus; RSV, respiratory syncytial virus.
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of cases having viruses at a higher viral load that might be indic-
ative of those with pneumonia due to that virus. Adenovirus, 
coronavirus 229, and PIV1–3 had a suggestion of a bimodal dis-
tribution among cases. The NP/OP viral load for the 2 cases with 
viruses detected in PCR of lung aspirates (ie, HMPV and adeno-
virus) fell within the distribution of viral loads for other cases, as 
well as controls, positive for that virus (Figure 2).
When constructing ROC curves, no virus had an AUC >0.8 
(Table 3). RSV had the highest AUC at 0.76, with only 3 other 
viruses having an AUC between 0.6 and 0.7 (influenza A, PIV1, 
and PIV3). Despite the low values for the AUC, when redefining 
positive for a virus as those with viral loads above the ROC optimal 
cutpoint value as determined by the Youden index, the odds ratio 
for predicting case status increased substantially for some viruses, 
approximately doubling for adenovirus, coronavirus 63, PIV2, and 
RSV (Table 4). Although the odds ratios increased, the population 
attributable fraction for most viruses did not change substantially, 
or even decreased (eg, influenza A, RSV) due to the lower fre-
quency of cases with densities above the optimal cutpoint (Figure 
3). This is because while the odds ratios are higher at the higher 
density cutoff, the prevalence of cases above the higher threshold 
was lower, and thus the proportion of PERCH cases assigned to 
the virus would not change appreciably by using the higher cutoff.
Predictors of Viral Load
We explored several potential predictors of viral density 
among cases. When NP/OP specimens were collected earlier 
in the course of illness, mean viral load was higher for RSV, 
PIV1, and PIV3 and was lower for adenovirus; no significant 
difference was observed for the other viruses (Supplementary 
Table 1). The viral load among cases did not vary by age for 
most viruses, including RSV, but a significant trend toward 
decreasing viral load with increasing age was observed for a 
few viruses, including adenovirus and RSV, which was also 
observed among controls (Supplementary Figure 2). A slight, 
but significant trend toward increasing viral load with increas-
ing age was seen for rhinovirus among cases, but a significant 
trend in the opposite direction was observed for controls. 
In general, viral load did not vary by study site. One notable 
exception was higher PIV1 viral load in The Gambia site (the 
only site with a PIV1 outbreak, data not shown). HIV-infected 
cases had a higher mean viral load for coronavirus 43 and a 
lower viral load for HMPV, PIV3, and RSV (Supplementary 
Table 2). There were no significant differences in the viral load 
between cases who were normally nourished vs malnourished 
(except PIV1 viral load was higher in normally nourished, 
data not shown).
We assessed whether viral load was associated with pneumo-
nia severity. Rhinovirus was the only virus with higher mean 
viral load for very severe pneumonia compared to severe pneu-
monia (Supplementary Figure  3). Influenza A  was the only 
virus with higher mean viral load in fatal compared with sur-
viving cases (Supplementary Figure 4). Furthermore, we com-
pared mean viral densities between cases with evidence of an 
other infiltrate (without alveolar consolidation) on chest radio-
graph to cases with evidence of alveolar consolidation (without 
evidence of an other infiltrate). No significant differences were 
found for any virus after adjusting for site and age.
DISCUSSION
In the PERCH study, the evidence for the utility of NP/OP 
viral load in distinguishing radiographically confirmed cases 
of severe or very severe pneumonia from controls was mixed. 
On the one hand, we found a higher mean viral load in NP/OP 
samples from severe and very severe pneumonia cases than from 
community controls without pneumonia for several respiratory 
viruses. Moreover, for many viruses, using a higher viral load 
threshold to define positivity that maximized the combination 
of sensitivity and specificity increased the odds ratio for case sta-
tus over a simple binary (presence/absence) definition of posi-
tivity based on viral detection, which has high sensitivity but low 
specificity. On the other hand, there was substantial overlap in 
the distribution of NP/OP viral load densities among cases and 
controls, even for RSV, the virus most strongly associated with 
case status. No cutoffs clearly distinguished cases from controls.
Table  3. Receiver Operating Characteristic Areas Under the Curve, 
Optimal Nasopharyngeal/Oropharyngeal Polymerase Chain Reaction 
Density Cutpoints for Determining Case Status, and Associated Positive 
Rate in Cases and Negative Rate in Controls by Virus Among Chest 
Radiograph–Positive Cases and Controls With Positive Densities—













Adenovirus 0.60 4.88 0.44 0.78
Coronavirus 43 0.57 6.94 0.36 0.74
Coronavirus 63 0.58 7.24 0.22 0.89
Influenza A 0.61 5.12 0.50 0.68
Influenza B 0.55 3.79 0.89 0.28
HBOV 0.54 5.81 0.20 0.89
HMPV A/B 0.54 3.9 0.91 0.20
Parainfluenza 1 0.65 4.62 0.75 0.55
Parainfluenza 2 0.54 5.64 0.26 0.91
Parainfluenza 3 0.69 4.75 0.81 0.54
PV/EV 0.53 4.38 0.40 0.71
Rhinovirus 0.56 3.64 0.55 0.56
RSV 0.76 6.30 0.84 0.59
Abbreviations: AUC, area under the curve; CXR+, chest radiograph positive; HBOV, human 
bocavirus; HMPV, human metapneumovirus; PV/EV, parechovirus/enterovirus; RSV, respi-
ratory syncytial virus.
aViruses with adjusted odds ratios <1 (see Table 2) were excluded from table (coronavirus 
229, coronavirus HKU, influenza C, and parainfluenza 4).
bCalculated using Youden index and, where possible, leave-one-out cross-validation. 
Leave-one-out cross-validation was not performed for influenza B, parainfluenza 2, or 
parechovirus/enterovirus.
cCXR+ defined as having radiographic evidence of pneumonia.
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Previous studies have also shown that the median or mean 
RSV concentration of NP/OP specimens among children is 
higher in cases of severe illness than among a healthy or mildly 
ill control population [7–10, 20, 21]. However, few of these 
studies compared the distribution of viral loads between severe 
cases and controls. Those that did compare these 2 groups 
showed an overlapping distribution similar to our study [8, 22]. 
Some studies of RSV viral load failed to show an association 
with severe lower respiratory tract infection [23, 24], but these 
studies included older children and adolescents in whom the 
Table 4. Nasopharyngeal/Oropharyngeal Prevalence of Viruses in Chest Radiograph–Positive Cases and Controls, Defining Positive as Any Detection of 
Virus and Detection of Virus Above an Optimal Viral Load Cutpoint as Determined by Receiver Operating Characteristic Curves; Odds of Determining Case 






(Above Optimal Cutpoint) AORe (95% CI)
Any Positive vs 
Negativef
AORe (95% CI)
Strong Positive vs 
Weak Positive/ 
NegativegCXR+ Casesb Controls CXR+ Casesb Controls CXR+ Casesb Controls
Adenovirus 1556 (90.5) 4384 (88.0) 92 (5.3) 470 (9.4) 72 (4.2) 126 (2.5) 0.88 (.73–1.07) 1.74 (1.28–2.36)
Coronavirus 43 1681 (97.7) 4785 (96.1) 25 (1.5) 149 (3.0) 14 (0.8) 43 (0.9) 0.52 (.36–.74) 0.81 (.44–1.49)
Coronavirus 63 1684 (97.9) 4819 (96.8) 28 (1.6) 147 (3.0) 8 (0.5) 11 (0.2) 0.63 (.43–.91) 1.78 (.71–4.47)
Influenza A 1658 (96.4) 4920 (98.9) 31 (1.8) 41 (0.8) 31 (1.8) 16 (0.3) 3.11 (2.15–4.49) 5.32 (2.87–9.85)
Influenza B 1702 (99.0) 4948 (99.4) 2 (0.1) 8 (0.2) 16 (0.9) 21 (0.4) 1.82 (1.00–3.32) 2.24 (1.15–4.36)
HBOV 1488 (86.6) 4316 (86.7) 184 (10.7) 593 (11.9) 47 (2.7) 68 (1.4) 1.11 (.94–1.31) 2.02 (1.38–2.96)
HMPV A/B 1534 (89.2) 4771 (95.9) 16 (0.9) 47 (0.9) 169 (9.8) 159 (3.2) 2.59 (2.09–3.21) 3.02 (2.40–3.82)
Parainfluenza 1 1630 (94.8) 4928 (99.0) 23 (1.3) 27 (0.5) 66 (3.8) 22 (0.4) 5.19 (3.60–7.49) 8.09 (4.92–13.32)
Parainfluenza 2 1697 (98.7) 4927 (98.9) 18 (1.0) 48 (1.0) 5 (0.3) 5 (0.1) 1.2 (.73–1.97) 2.55 (.72–9.04)
Parainfluenza 3 1616 (94.0) 4838 (97.1) 21 (1.2) 78 (1.6) 83 (4.8) 64 (1.3) 2.13 (1.63–2.77) 3.52 (2.51–4.92)
PV/EV 1589 (92.4) 4555 (91.5) 79 (4.6) 303 (6.1) 52 (3.0) 122 (2.4) 0.91 (.74–1.12) 1.22 (.87–1.71)
Rhinovirus 1260 (73.3) 3675 (73.8) 211 (12.3) 743 (14.9) 249 (14.5) 559 (11.2) 0.94 (.82–1.07) 1.26 (1.07–1.48)
RSV 1259 (73.2) 4840 (97.2) 73 (4.2) 83 (1.7) 388 (22.6) 57 (1.1) 12.55 (10.24–15.38) 24.72 (18.52–33.01)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CXR+, chest radiograph positive; HBOV, human bocavirus; HMPV, human metapneumovirus; PV/EV, parechovirus/entero-
virus; RSV, respiratory syncytial virus.
aViruses with adjusted odds ratios <1 for association of density (log copies/mL) with case status excluded from table (coronavirus 229, coronavirus HKU, influenza C, and parainfluenza 
virus 4 as noted in Table 2).
bCXR+ defined as having radiographic evidence of pneumonia.
cWeakly positive: positive density below optimal cutpoint determined by Youden index. See Table 3.
dStrongly positive: density above optimal cutpoint determined by Youden index. See Table 3.
eOdds ratios adjusted for site and age. Bolded values are significant (P < .05).
fAny positive includes those below and above optimal cutoff.
gStrong positives are compared with combined negatives and weak positives.
Figure 3. Adjusted population attributable fraction (PAF) for chest radiograph–positive cases using 2 methods: any positive vs negative (AF1) and positive above optimal 
cutpoint vs positive below optimal cutpoint and negative (AF2)— Pneumonia Etiology Research for Child Health (PERCH) study, August 2011–January 2014. PAF = population 
prevalence × (1 – 1 / odds ratio). Odds ratio (OR) is adjusted for other viruses, site, and age. Confidence intervals calculated using bootstrapping method. PAF not shown 
where adjusted OR was <1 resulting in negative PAF. Abbreviations: Adeno, adenovirus; AF, attributable fraction; Boca, human bocavirus; Flu, influenza virus; HCoV, human 
coronavirus; HMPV, human metapneumovirus; Para, parainfluenza virus; PV/EV, parechovirus/enterovirus.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S337/3858230
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S344 • CID 2017:64 (Suppl 3) • Feikin et al
pathogenic significance of detecting RSV in the NP/OP is less 
clear. One study of RSV viral load in infants showed no associa-
tion with severe bronchiolitis [25] while another suggested that 
viral load only influences clinical severity for first RSV infec-
tions in young infants [10].
In some studies, influenza viral load was associated with 
severe disease [4, 26–29], while in others there was no associa-
tion [8, 23, 27, 30–32]. A few studies have shown a higher viral 
load in severe cases for HMPV [24, 33, 34]. Higher viral loads of 
HBOV in nasopharyngeal aspirates were associated with greater 
severity of illness among Chinese children [35]. Rhinovirus 
viral load has been associated with more severe illness [22], but 
not in some studies [8, 21]. Again, the majority of these studies 
looked only at the central tendency of the viral load and did not 
demonstrate a clear dichotomy in the distribution of viral loads 
based on case status or severity category.
We did not find a higher viral load associated with greater 
severity among pneumonia cases for most viruses. Cases who 
died had a similar viral load as those who survived, and those 
with very severe pneumonia had similar viral loads to those 
children with severe pneumonia. This is in contrast with some 
other studies of viruses in which higher viral load was observed 
among RSV-infected children requiring mechanical ventilation 
[9], and severe acute respiratory syndrome coronavirus– and 
Middle East respiratory syndrome coronavirus–infected adults 
who died [36, 37].
We undertook this analysis, in part, to determine if viral 
loads of NP/OP specimens could be incorporated into the 
PERCH analysis to identify etiologies of severe/very severe 
pneumonia. Using a higher density threshold also did not have 
an appreciable effect on the population attributable fraction for 
most viruses, suggesting that using higher thresholds to assign 
viral etiology to cases would likely have little impact on the 
analysis of the etiologic distribution among the population of 
PERCH cases [38]. In the final PERCH analyses, we will be able 
to run sensitivity analyses to assess the impact of incorporating 
viral density thresholds on the assessment of etiology.
In contrast to the accompanying analyses of bacterial pneu-
monia, our conclusions about the interpretation of viral load 
and whether to include it in the main PERCH etiology analysis 
were limited by the lack of a gold standard to diagnose viral 
pneumonia [5, 16]. There were few PERCH cases who under-
went lung aspirate procedures and even fewer who had a lung 
aspirate in which a virus was detected in their lungs. Among a 
population of pneumonia cases in which a virus was detected in 
the NP/OP, there was likely a mixture of those in whom the virus 
had a causal role in pneumonia and those in whom it did not. 
The inability to identify which children had pneumonia due to 
which virus hampered the study’s ability to determine if higher 
viral loads in the NP/OP were associated with pneumonia.
Besides the lack of a gold standard, other limitations might 
have affected our results. First, specimens were taken at one 
point in time on admission to the hospital. We observed that 
viral load varied with the time since illness onset, with higher 
viral load earlier in the course of symptomatic illness for some 
viruses. Taking sequential samples in which we could compare 
the peak viral load between cases of different clinical severity 
would have been optimal. Second, our design precluded us 
from assessing the role of viral load in the lung. Upper respira-
tory tract viral load might reflect the amount of replication in 
the local epithelial cells rather than the viral burden in the lung 
parenchyma. Evaluation of viral load of specimens from the 
lung, either through lung aspirates or bronchoalveolar lavage, 
would provide more direct evidence of the role of viral load in 
pneumonia severity.
The widespread use of sensitive PCR assays for testing NP/
OP specimens has led to a higher reported prevalence of pneu-
monias attributed to respiratory viruses in both adults and 
children [2]. Due to the high prevalence of viral infections of 
the URT itself, however, it is difficult to conclude that detection 
of a virus in the URT of a pneumonia patient is equivalent to 
having pneumonia due to that virus. In the PERCH study, the 
viral loads in the NP/OP of pneumonia patients are unlikely 
to further clarify the role of that virus in causing pneumonia. 
However, the PERCH study design was not optimal to answer 
this question definitively. Further research, such as longitudi-
nal studies and animal models, is needed to better elucidate the 
interpretation of viral load in the diagnosis and clinical man-
agement of viral pneumonia.
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